Abstract
This article introduces the bedside methylene blue nephrostogram (BMBN) as a rapid, cost-effective alternative to traditional imaging for confirming ureteral patency post-percutaneous nephrolithotomy (PCNL). The study details the procedure, supported by case studies, demonstrating its potential to expedite patient discharge, reduce hospital stays, and alleviate healthcare costs in Australian public hospitals.